Lupin launches drugs to cure leukaemia
Lupin launches drugs to cure leukaemia

Lupin launches drugs to cure leukaemia

Amir Shaikh Article rating: 5.0

Pharma major Lupin informed the bourses that it has launched Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Shital Jibhe Article rating: 5.0

The markets on July 09, 2019 opened gap down. BSE Sensex is trading at 38,672.61, down by 47.96 points and the Nifty is trading at 11,532.40, down by 26.20 points.

Meghmani Organics starts commercial operation of CMS project
Meghmani Organics starts commercial operation of CMS project

Meghmani Organics starts commercial operation of CMS project

Nidhi Jani Article rating: 3.6

Expansion of MDC would help the company to meet the growing demand of pharma and agrochemical customers, while Chloroform will meet demand for raw material in the pharma sector and refrigerant gas segment.

Voltas enters partnership with EESL for 5 star ACs
Voltas enters partnership with EESL for 5 star ACs

Voltas enters partnership with EESL for 5 star ACs

Pratik Shastri Article rating: 3.5

India’s leading AC manufacturer, Voltas Limited announced that it has entered into a partnership with Energy Efficient Services Limited (EESL) for production of energy efficient air conditioners.

Glenmark Pharma gets ANDA approval for Ranolazine
Glenmark Pharma gets ANDA approval for Ranolazine

Glenmark Pharma gets ANDA approval for Ranolazine

DSIJ Intelligence Article rating: 5.0

Glenmark Pharmaceuticals Inc. has received final approval from United States Food & Drug Administration (USFDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg.

Mutual Funds Unlocked: Fundamental analysis of funds
Mutual Funds Unlocked: Fundamental analysis of funds

Mutual Funds Unlocked: Fundamental analysis of funds

DSIJ Intelligence Article rating: 4.5

Mutual fund schemes are generally analysed from its historical price and returns, however they can and should be fundamentally analysed to make appropriate investment decesion. 

RSS
First32803281328232833285328732883289Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR